A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

NCT07709494 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants
Non-cystic Fibrosis Bronchiectasis

Interventions

COMBINATION_PRODUCT: Rev-56 for Inhalation
DRUG: Placebo: Normal saline

Sponsor

Revagenix, Inc.

Collaborators

[object Object]